Mvabea (Modified Vaccinia Ankara - Bavarian Nordic Virus Encoding The Ebola Virus Zaire Mayinga Strain Glyco)

The vaccine uses a Modified Vaccinia Ankara (MVA) viral vector that has been genetically engineered to express the Ebola virus glycoprotein. After intramuscular injection, the vector delivers this antigen to host cells, prompting the immune system to generate both antibody and T‑cell responses that recognize and neutralise the Ebola virus.

The exact dose and schedule of Mvabea are determined by the prescribing healthcare professional based on regulatory guidelines and the patient’s risk profile. The prescriber will decide the volume, number of doses, and interval between administrations appropriate for each individual.

Data on the use of Mvabea in pregnant or breastfeeding individuals are limited. It should only be administered when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Mvabea, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Mvabea (MVA‑based) differs from the recombinant vesicular stomatitis virus (rVSV‑ZEBOV) vaccine in its vector platform and storage requirements. MVA is a non‑replicating vector, which may be preferred for immunocompromised patients, while rVSV is replication‑competent and may elicit a faster immune response. Both aim to prevent Zaire ebolavirus infection but have distinct safety and logistical profiles.

Mvabea must be stored in a refrigerated environment at 2 °C to 8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport and storage is essential to preserve vaccine potency.

Mvabea is given as an intramuscular injection, typically into the deltoid muscle of the upper arm. The injection is performed by a qualified healthcare professional using aseptic technique. The exact volume and number of injections are prescribed by the treating clinician.

Serious adverse events, although rare, include severe allergic reactions such as anaphylaxis, neurological complications like Guillain‑Barré syndrome or encephalitis, and cardiac inflammation (myocarditis or pericarditis). Patients should be observed for immediate reactions and instructed to seek medical attention if they develop symptoms such as difficulty breathing, swelling of the face or throat, or neurological signs.

Mvabea is contraindicated in individuals with a known severe allergy to any component of the vaccine. Persons with untreated severe immunodeficiency (e.g., advanced HIV infection) should avoid the vaccine unless a risk‑benefit assessment justifies use. Pregnant or breastfeeding individuals should only receive it when the potential benefit outweighs the uncertain risk.